The PI3K pathway is the most frequently altered pathway in cancer, and its activation has been shown to confer resistance to endocrine and HER2-targeted therapies preclinically.
Ingrid A. Mayer, MD, MSCI
Advertisement
Articles by Ingrid A. Mayer, MD, MSCI
Advertisement
Latest Updated Articles
Development of PI3K Inhibitors in Breast CancerNovember 7th 2014
Advertisement
Advertisement
Trending on OncLive
1
JNJ-87189401 Plus Pasritamig Drives Deep PSA Responses With Favorable Safety in Pretreated mCRPC
2
STX-001 Produces Durable Systemic Responses in PD-1–Resistant Melanoma
3
RP1 Plus Nivolumab Preserves Quality-Adjusted Survival in Advanced Melanoma After Anti–PD-1 Therapy
4
Afami-Cel Outcomes Are Tied to MAGE-A4 Expression, Tumor Burden in Synovial Sarcoma
5